CGTN
20.3.2021 13:19:10 CET | Business Wire | Press release
Chinese archaeologists announced on Saturday that some new major discoveries have been made at the legendary Sanxingdui Ruins site in southwest China, helping shed light on the cultural origins of the Chinese nation.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210320005008/en/
Archaeologists have found six new sacrificial pits and unearthed more than 500 items dating back about 3,000 years at the Sanxingdui Ruins in Sichuan Province, the National Cultural Heritage Administration (NCHA) announced in the provincial capital Chengdu.
Over 500 precious cultural relics discovered
Ranging from 3.5 to 19 square meters, these six sacrificial pits, which were discovered from November 2019 to May 2020, are in rectangular shape, according to NCHA. Among them, pits No.3, No.4, No.5 and No.6 have been excavated to the utensil layer so far, while pits No.7 and No.8 are being backfilled.
Together they form an area in which people of the ancient Shu civilization offered sacrifices to heaven, Earth and their ancestors, and prayed for prosperity and peace, according to Tang Fei, head of the excavation team at Sanxingdui and chief of the Sichuan Provincial Cultural Relics and Archaeology Research Institute.
The discoveries have shown the distinctiveness of the Shu civilization and the diversity of the Chinese civilization, said Ran Honglin, another researcher with the institute.
In addition, over 500 pieces of important cultural relics have been unearthed from these six pits, including the fragments of gold masks, bird-shaped gold ornaments, gold foil, painted bronze head portraits, giant bronze masks, bronze sacred tree, ivory, fragments of exquisite tooth carvings, jade cong and jade tools.
A gold mask has been unearthed at the No.5 sacrificial pit. With an area of about three square meters, it is the smallest pit, but it's where the most gold pieces were unearthed, according to archaeologists.
During the process, archaeologists have made full use of modern scientific and technological means to build an archaeological excavation cabin, integrated excavation platform and multi-functional excavation operation system.
With the support of professional teams of multiple disciplines and institutions, they have formed an integrated work mode combining traditional archaeology, laboratory archaeology, technological archaeology as well as the protection of cultural relics. The combination will ensure the high quality and high level of archaeological work, NCHA said at the conference.
Meanwhile, the NCHA has identified the "Research on the Civilization Process of Bashu in Sichuan-Chongqing Region" as a major program of the "Archaeological China" project, aiming to conduct in-depth study on the evolution of civilization in the region and its integration into the overall cultural landscape of the pluralistic unity of the Chinese nation.
Located in the city of Guanghan, some 40 kilometers from Sichuan's provincial capital Chengdu, the Sanxingdui Ruins site is regarded one of the most important archaeological discoveries in the 20th century. The excavation has lasted for nearly 100 years since the first discovery in the late 1920s.
In 1986, archaeologists found two large-scale sacrificial pits dating back to the Shang Dynasty (1600-1046 BC). Thousands of rare treasures were discovered from the two pits.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210320005008/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
